Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 268

Results For "IMI"

4819 News Found

Zydus receives final approval from the USFDA for Sugammadex Single-Dose Vial
Drug Approval | October 09, 2023

Zydus receives final approval from the USFDA for Sugammadex Single-Dose Vial

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide


Reclassify nicotine replacement therapies as prescription drugs, says Doctor
News | October 07, 2023

Reclassify nicotine replacement therapies as prescription drugs, says Doctor

NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts


Lupin receives tentative approval from USFDA for Tolvaptan Tablets
Drug Approval | October 07, 2023

Lupin receives tentative approval from USFDA for Tolvaptan Tablets

Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)


Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates
News | October 06, 2023

Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates

The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation


Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules
Drug Approval | October 05, 2023

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals


Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets
Drug Approval | October 05, 2023

Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets

The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products


Emmes appoints Matt Bond as CFO
People | October 05, 2023

Emmes appoints Matt Bond as CFO

His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy


Alembic received 6 USFDA approvals during Q2FY24
Drug Approval | October 05, 2023

Alembic received 6 USFDA approvals during Q2FY24

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets


Strides receives USFDA approval for Icosapent Ethyl capsules
Drug Approval | October 04, 2023

Strides receives USFDA approval for Icosapent Ethyl capsules

The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin


Lupin launches patient support program ‘Humrahi‘  for diabetes management
Healthcare | October 04, 2023

Lupin launches patient support program ‘Humrahi‘ for diabetes management

India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045